![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA OKs BioTime Wound Management Hydrogel
FDA OKs BioTime Wound Management Hydrogel
![](https://www.fdanews.com/ext/resources/test/Device_Images2/BioTime_Logo.gif?t=1433991647&width=430)
The FDA has granted 510(k) clearance to BioTime’s Premvia HyStem hydrogel for the management of a wide range of wounds, including diabetic ulcers, second-degree burns and draining wounds.
Premvia mimics the body’s natural extracellular matrix by cross linking collagen and hyaluronic acid, making it compatible with cells and tissues, said Gregory Keller, co-director of the UCLA facial plastic surgery fellowship.
The FDA clearance — the company’s first — lays the foundation for more bioactive and cell-matrix combination products in the HyStem hydrogel line, BioTime said.
The company estimates the global market for aesthetic and reconstructive surgery at more than $6 billion annually. Premvia is expected to serve a subset of the overall market. — Kellen Owings
Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.
Upcoming Events
-
21Oct